Original site: www.cdc.gov/mmwr/preview/mmwrhtml/00056719.htm RestoredCDC.org is an independent project and is not affiliated with, endorsed by, or associated with the Centers for Disease Control and Prevention (CDC) or any government entity. The CDC provides information free of change at CDC.gov. Note the following: 1) Due to archival on January 6, 2025, no information on recent outbreaks is available. 2) Videos have not been restored. 3) Use of this site implies acceptance of this disclaimer.
Summary Table. Rotavirus Vaccine for the Prevention of Rotavirus Gas Among Children Recommendations of the Advisory Committee on
Immunization Practices (ACIP)
Summary Table. Recommendations and Quality of Evidence
Rotavirus Vaccine Recommendations
Advisory Committee on Immunization Practices, 1999
(Table_1) Table_1 Note:
To print large tables and graphs users may have to change their printer settings to landscape and use a small font size.
Summary Table. Recommendations and Quality of Evidence
Rotavirus Vaccine Recommendations Advisory Committee on Immunization Practices, 1999
=====================================================================================================================================
Level of Strength of
Recommendations Evidence* Evidence+
-------------------------------------------------------------------------------------------------------------------------------------
Provide routine vaccination at 2,4,and 6 months of age. I A
Administer to breastfed infants. I A
Administer with DTP (or DTaP),Hib vaccine,OPV,IPV,and hepatitis B vaccine. I A
Administer to infants with mild illnesses. I B
Not recommended for
Infants with known or suspected immunodeficiency III C
Infants with hypersensitivity to vaccine components III B
Infants with acute gastrointestinal disease III C
Infants with moderate to severe febrile illness III C
Precautions and special situations
Premature infants (<37 weeks gestational age) III C
Infants living in households with immunocompromised persons III C
Timing of administration of antibody-containing blood products and rotavirus vaccination III C
Infants with preexisting chronic gastrointestinal illnesses III C
Vaccine that is regurgitated III C
Late or incomplete immunization III C
Children hospitalized after vaccination III C
-------------------------------------------------------------------------------------------------------------------------------------
* Level of Evidence
I Evidence from randomized, controlled trials
II Evidence from other epidemiologic studies
III Opinions of authorities
+ Strength of Evidence
A Good evidence to support recommendation
B Fair evidence to support recommendation
C Insufficient evidence
=====================================================================================================================================
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
